Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review

Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those wh...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 13; no. 21; p. 5477
Main Authors Freitas, Ana Julia Aguiar de, Causin, Rhafaela Lima, Varuzza, Muriele Bertagna, Hidalgo Filho, Cassio Murilo Trovo, Silva, Vinicius Duval da, Souza, Cristiano de Pádua, Marques, Márcia Maria Chiquitelli
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 31.10.2021
MDPI
Subjects
Biomarkers
Breast cancer
Chemotherapy
DNA methylation
Genomics
Mutation
Patients
Precision medicine
Proteomics
Review
Transcriptomics
Tumors
Online AccessGet full text

Cover

More Information
Summary:Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new “OMICS” technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work and share first authorship.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13215477